NO2310396T3 - - Google Patents

Info

Publication number
NO2310396T3
NO2310396T3 NO09793887A NO09793887A NO2310396T3 NO 2310396 T3 NO2310396 T3 NO 2310396T3 NO 09793887 A NO09793887 A NO 09793887A NO 09793887 A NO09793887 A NO 09793887A NO 2310396 T3 NO2310396 T3 NO 2310396T3
Authority
NO
Norway
Application number
NO09793887A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2310396T3 publication Critical patent/NO2310396T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO09793887A 2008-07-08 2009-07-08 NO2310396T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04
EP09793887.2A EP2310396B1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors
PCT/EP2009/004942 WO2010003658A1 (en) 2008-07-08 2009-07-08 Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
NO2310396T3 true NO2310396T3 (cg-RX-API-DMAC10.html) 2018-02-03

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09793887A NO2310396T3 (cg-RX-API-DMAC10.html) 2008-07-08 2009-07-08

Country Status (31)

Country Link
US (2) US8921355B2 (cg-RX-API-DMAC10.html)
EP (1) EP2310396B1 (cg-RX-API-DMAC10.html)
JP (2) JP5426671B2 (cg-RX-API-DMAC10.html)
KR (1) KR101640374B1 (cg-RX-API-DMAC10.html)
CN (1) CN102089314B (cg-RX-API-DMAC10.html)
AP (1) AP2743A (cg-RX-API-DMAC10.html)
AR (1) AR072726A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009267389B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0915887B8 (cg-RX-API-DMAC10.html)
CA (1) CA2729307C (cg-RX-API-DMAC10.html)
CL (1) CL2011000032A1 (cg-RX-API-DMAC10.html)
CO (1) CO6351793A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110076A (cg-RX-API-DMAC10.html)
DK (1) DK2310396T3 (cg-RX-API-DMAC10.html)
EA (1) EA019008B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11010750A (cg-RX-API-DMAC10.html)
ES (1) ES2651038T3 (cg-RX-API-DMAC10.html)
HN (1) HN2011000072A (cg-RX-API-DMAC10.html)
HR (1) HRP20171892T1 (cg-RX-API-DMAC10.html)
HU (1) HUE035244T2 (cg-RX-API-DMAC10.html)
IL (1) IL210086A (cg-RX-API-DMAC10.html)
LT (1) LT2310396T (cg-RX-API-DMAC10.html)
MX (1) MX2011000276A (cg-RX-API-DMAC10.html)
NI (1) NI201100010A (cg-RX-API-DMAC10.html)
NO (1) NO2310396T3 (cg-RX-API-DMAC10.html)
NZ (2) NZ603343A (cg-RX-API-DMAC10.html)
SI (1) SI2310396T1 (cg-RX-API-DMAC10.html)
SV (1) SV2011003796A (cg-RX-API-DMAC10.html)
TW (1) TWI454476B (cg-RX-API-DMAC10.html)
UY (1) UY31973A (cg-RX-API-DMAC10.html)
WO (1) WO2010003658A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910177B (zh) 2007-12-24 2013-08-28 泰博特克药品公司 作为丙型肝炎病毒抑制剂的大环吲哚
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
MX2012011963A (es) 2010-04-13 2012-12-17 Janssen Pharmaceuticals Inc Combinacion de un inhibidor macrociclico del virus de la hepatitis c, un no-nucleosido y un nucleosido.
EP2585438B1 (en) * 2010-06-24 2014-08-20 Janssen R&D Ireland PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
WO2013030803A1 (en) 2011-09-02 2013-03-07 Novartis Ag Choline salt of an anti - inflammatory substituted cyclobutenedione compound
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
JP2015526504A (ja) 2012-08-31 2015-09-10 ヤンセン ファーマシューティカルズ,インコーポレーテッド Hcvの大環状プロテアーゼ阻害剤と、非ヌクレオシドhcv阻害剤と、リトナビルとの組み合わせ
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN116425782A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) * 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
CZ301802B6 (cs) * 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem
KR100891240B1 (ko) 2000-08-30 2009-04-01 파나소닉 주식회사 플라즈마 디스플레이 표시장치 및 그 제조방법
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US20090221559A1 (en) 2005-09-02 2009-09-03 Jean-Francois Bonfanti Benzodiazepines as hcv inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
HRP20110193T1 (hr) 2006-10-10 2011-05-31 Medivir Ab Inhibitor hcv nukleozida
US8101595B2 (en) * 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
AU2008277442A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
SMT201700121T1 (it) 2009-02-27 2017-03-08 Janssen Pharmaceuticals Inc Sale amorfo di un inibitore macrociclico di hcv
MX2012011963A (es) 2010-04-13 2012-12-17 Janssen Pharmaceuticals Inc Combinacion de un inhibidor macrociclico del virus de la hepatitis c, un no-nucleosido y un nucleosido.
EP2585438B1 (en) 2010-06-24 2014-08-20 Janssen R&D Ireland PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
JP2015526504A (ja) 2012-08-31 2015-09-10 ヤンセン ファーマシューティカルズ,インコーポレーテッド Hcvの大環状プロテアーゼ阻害剤と、非ヌクレオシドhcv阻害剤と、リトナビルとの組み合わせ

Also Published As

Publication number Publication date
IL210086A0 (en) 2011-02-28
KR20110040889A (ko) 2011-04-20
US8921355B2 (en) 2014-12-30
AU2009267389B2 (en) 2013-05-30
JP5426671B2 (ja) 2014-02-26
JP2011527299A (ja) 2011-10-27
TW201014865A (en) 2010-04-16
ES2651038T3 (es) 2018-01-23
AP2743A (en) 2013-09-30
NZ603343A (en) 2013-08-30
KR101640374B1 (ko) 2016-07-18
BRPI0915887B1 (pt) 2020-02-18
MX2011000276A (es) 2011-03-02
CL2011000032A1 (es) 2011-07-15
HK1155734A1 (en) 2012-05-25
EP2310396B1 (en) 2017-09-06
EA019008B1 (ru) 2013-12-30
TWI454476B (zh) 2014-10-01
AU2009267389A8 (en) 2013-07-04
CN102089314A (zh) 2011-06-08
CA2729307A1 (en) 2010-01-14
WO2010003658A1 (en) 2010-01-14
LT2310396T (lt) 2017-12-27
HN2011000072A (es) 2013-09-01
SI2310396T1 (en) 2018-01-31
SV2011003796A (es) 2011-04-08
UY31973A (es) 2010-01-29
US20140107101A1 (en) 2014-04-17
US20110105473A1 (en) 2011-05-05
HUE035244T2 (hu) 2018-05-02
BRPI0915887B8 (pt) 2021-05-25
CR20110076A (es) 2011-11-10
NI201100010A (es) 2011-09-07
NZ590073A (en) 2012-11-30
CN102089314B (zh) 2014-07-23
BRPI0915887A2 (pt) 2015-11-03
DK2310396T3 (en) 2017-12-11
US9427440B2 (en) 2016-08-30
EP2310396A1 (en) 2011-04-20
ECSP11010750A (es) 2011-08-31
EA201170153A1 (ru) 2011-08-30
AU2009267389B8 (en) 2013-07-04
JP5808370B2 (ja) 2015-11-10
CO6351793A2 (es) 2011-12-20
AR072726A1 (es) 2010-09-15
AP2010005521A0 (en) 2010-12-31
JP2014028818A (ja) 2014-02-13
IL210086A (en) 2014-05-28
AU2009267389A1 (en) 2010-01-14
CA2729307C (en) 2017-08-29
HRP20171892T1 (hr) 2018-01-12

Similar Documents

Publication Publication Date Title
BR112016019572A2 (cg-RX-API-DMAC10.html)
BRPI0909040A2 (cg-RX-API-DMAC10.html)
BRPI0917573A2 (cg-RX-API-DMAC10.html)
BRPI0908549B8 (cg-RX-API-DMAC10.html)
BRPI0918697A2 (cg-RX-API-DMAC10.html)
BRPI0917525A2 (cg-RX-API-DMAC10.html)
BRPI0920750A2 (cg-RX-API-DMAC10.html)
BRPI0917618A8 (cg-RX-API-DMAC10.html)
BRPI0922455A2 (cg-RX-API-DMAC10.html)
BRPI0923734A2 (cg-RX-API-DMAC10.html)
BRPI0922669A2 (cg-RX-API-DMAC10.html)
BRPI0908285A2 (cg-RX-API-DMAC10.html)
BRPI0910485A2 (cg-RX-API-DMAC10.html)
BRPI0914750A2 (cg-RX-API-DMAC10.html)
BRPI0919811A2 (cg-RX-API-DMAC10.html)
BRPI0915616A2 (cg-RX-API-DMAC10.html)
BRPI0908120A2 (cg-RX-API-DMAC10.html)
BRPI0904541A8 (cg-RX-API-DMAC10.html)
BRPI0920914A2 (cg-RX-API-DMAC10.html)
BRPI0922550A2 (cg-RX-API-DMAC10.html)
BRPI0916284A2 (cg-RX-API-DMAC10.html)
BRPI0913605A2 (cg-RX-API-DMAC10.html)
BRPI0911617A2 (cg-RX-API-DMAC10.html)
BRPI0914852A2 (cg-RX-API-DMAC10.html)
CH2347250H2 (cg-RX-API-DMAC10.html)